Forefront Analytics, LLC Athira Pharma, Inc. Transaction History

Forefront Analytics, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.92 - $2.71 $49,879 - $70,403	25,979 Added 126.01%	46,595 $123,000
Q1 2024 May 15, 2024	SELL	$2.24 - $4.15 $20,493 - $37,968	-9,149 Reduced 30.74%	20,616 $56,000
Q4 2023 Feb 13, 2024	BUY	$1.39 - $2.46 $12,447 - $22,029	8,955 Added 43.03%	29,765 $72,000
Q2 2023 Aug 11, 2023	SELL	$2.36 - $3.59 $1,923 - $2,925	-815 Reduced 3.77%	20,810 $61,000
Q1 2023 May 11, 2023	SELL	$2.26 - $4.22 $1,638 - $3,059	-725 Reduced 3.24%	21,625 $54,000
Q4 2022 Feb 13, 2023	BUY	$2.76 - $3.71 $61,685 - $82,918	22,350 New	22,350 $70,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $23.4M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Forefront Analytics, LLC, based on Form 13F filings with the SEC.

Stay updated on Forefront Analytics, LLC with notifications on news.